Annovis's PR shows how the market is starved for news of Alzheimer's progress and the carry along phenomenon for Alzheimer's drug progress. Anavex is mentioned as one of those companies that will possibly be affected by the Biogen Aducanumab decision. Could the next positive Anavex PR have the same reaction?
Market Data 
Markets 
AI
